Company news
Allogene Therapeutics, Inc. news in 2020
Allogene Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
December 22, 2020
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
December 14, 2020
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
December 6, 2020
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
December 1, 2020
Allogene Therapeutics Reports Third Quarter 2020 Financial Results
November 3, 2020
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology
November 3, 2020
Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020
October 26, 2020
Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)
October 14, 2020
Allogene Therapeutics Reports Second Quarter 2020 Financial Results
August 4, 2020
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
July 6, 2020
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
June 30, 2020
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
June 21, 2020
Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
June 2, 2020
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
May 31, 2020
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
May 28, 2020
Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
May 25, 2020
Allogene Therapeutics Reports First Quarter 2020 Financial Results
May 5, 2020
Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
April 28, 2020
Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020
April 26, 2020
Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
February 5, 2020
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
January 12, 2020